News
NEW YORK, April 26, 2025--Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback